Nanovibronix Inc SEC Filings

NAOV NASDAQ

Welcome to our dedicated page for Nanovibronix SEC filings (Ticker: NAOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading NanoVibronix’s SEC disclosures can feel like sorting clinical trials from accounting notes. Every 10-K details FDA clearance milestones for PainShield, UroShield, and WoundShield, yet those critical updates hide inside hundreds of pages. Our platform turns that problem on its head.

Stock Titan’s AI summarizes each filing the moment it hits EDGAR, delivering plain-English answers to the questions investors actually type into search: “NanoVibronix annual report 10-K simplified” or “understanding NanoVibronix SEC documents with AI.” Whether you need the latest NanoVibronix quarterly earnings report 10-Q filing to track PainShield sales, or want NanoVibronix Form 4 insider transactions real-time to see when executives buy shares, the information is ready and translated into actionable insight.

Here’s what you’ll uncover:

10-K & 10-Q – AI-highlighted revenue trends, R&D spend, and reimbursement risks, perfect for rapid NanoVibronix earnings report filing analysis.
8-K – Material clinical results and distribution agreements, with NanoVibronix 8-K material events explained in context.
Form 4 – Track NanoVibronix insider trading Form 4 transactions and spot patterns in NanoVibronix executive stock transactions Form 4.
DEF 14A – A concise look at NanoVibronix proxy statement executive compensation so you know how leadership is paid.

No more hunting through appendices. With real-time alerts, expert commentary, and AI-powered summaries, NanoVibronix SEC filings explained simply becomes reality—so you can focus on how low-intensity ultrasound is changing patient care, not on deciphering legalese.

06/25/2025 04:05 PM

Filing

[DEFA14A] NanoVibronix, Inc. Additional Proxy Soliciting Materials

Rhea-AI Summary

NanoVibronix (NAOV) has filed a DEFA14A to correct an error in their previously filed proxy statement for the Special Meeting scheduled for July 11, 2025. The key correction relates to the outstanding preferred stock disclosure as of May 16, 2025 (Record Date).

The corrected share structure includes:

Common Stock: 2,282,746 shares
Series G Preferred Stock: 320,348 shares
Series X Preferred Stock: 57,720 shares

The company clarifies that no Series C, D, E, or F Preferred Stock are outstanding. Each common share carries one vote, with no cumulative voting rights. Stockholders who have already submitted their proxy votes do not need to take action unless they wish to change their vote. The stockholder list will be available for inspection at the company's headquarters for 10 days before the meeting.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

[DEF 14A] NanoVibronix, Inc. Definitive Proxy Statement

Rhea-AI Summary

NanoVibronix has announced a Special Meeting of Stockholders to be held virtually on July 11, 2025, primarily to vote on a proposed reverse stock split. The company is seeking approval for a reverse split ratio ranging from 1-for-2 to 1-for-50, to be implemented at the Board's discretion within one year of approval.

Key points for consideration:

The reverse split is preemptively proposed to maintain Nasdaq compliance, as the stock price recently closed below $1.00 on May 28, 2025
Current shares outstanding: 2,282,746 shares of Common Stock
Record date for voting eligibility: May 16, 2025
Meeting will be held virtually at www.virtualshareholdermeeting.com/NAOV2025SM2

The Board recommends voting FOR both the Reverse Stock Split Proposal and the Adjournment Proposal. This strategic move aims to ensure continued Nasdaq listing compliance and maintain market stability for shareholders.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Nanovibronix (NAOV)?

The current stock price of Nanovibronix (NAOV) is $1.17 as of June 28, 2025.

What is the market cap of Nanovibronix (NAOV)?

The market cap of Nanovibronix (NAOV) is approximately 2.4M.

What is NanoVibronix Inc focused on?

NanoVibronix Inc is focused on developing noninvasive medical devices that utilize low intensity ultrasound technology for pain management, wound healing, and biofilm prevention.

How does the company generate revenue?

NanoVibronix generates revenue through the direct sale of its device systems to patients and through agreements with distributors, ensuring broad market coverage.

What are the primary products offered by NanoVibronix?

The company offers a suite of products including devices like UroShield, PainShield, and WoundShield, all of which are designed to deliver therapeutic low-frequency ultrasound treatments.

What is unique about NanoVibronix's technology?

Its proprietary technology is based on low intensity acoustic waves transmitted by miniature transducers, which uniquely enable therapeutic applications in a noninvasive and home-based setting.

How do NanoVibronix devices benefit patients?

The devices promote tissue repair, reduce pain, accelerate wound healing, and prevent biofilm formation on catheters, providing a simple and user-friendly solution for home healthcare.

What makes NanoVibronix's approach different from other medical devices?

NanoVibronix distinguishes itself by focusing on low cost, noninvasive ultrasound-based treatments that can be easily administered outside of traditional clinical environments.

Are NanoVibronix products regulated for safety?

Yes, the company ensures that its products meet stringent regulatory standards, with approvals such as FDA clearance affirming the safety and effectiveness of its technology.

How does NanoVibronix contribute to biofilm prevention?

Through its innovative UroShield product, the company uses low intensity ultrasound to disrupt biofilm formation on urinary catheters, thereby reducing the risk of urinary tract infections.